Xiangmin Cui - Sep 28, 2021 Form 4 Insider Report for Cue Health Inc. (HLTH)

Role: Director
Signature: /s/ Erica Palsis, Attorney-in-Fact for Xiangmin Cui
Stock symbol: HLTH
Transactions as of: Sep 28, 2021
Transactions value $: $10,092,045
Form type: 4
Date filed: 9/30/2021, 05:43 PM
Previous filing: Sep 23, 2021
Next filing: Jan 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HLTH	Common Stock	Conversion of derivative security		+8.19M			8.19M	Sep 28, 2021	See Footnote	F1, F2
transaction	HLTH	Common Stock	Award	$10.1M	+788K		$12.80^*	788K	Sep 28, 2021	See Footnote	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HLTH	Series C-1 Preferred Stock	Conversion of derivative security	$0	-8.19M	-100%	$0.00^*	0	Sep 28, 2021	Common Stock	8.19M		See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. The reporting person is the manager of the GP and disclaims beneficial ownership of such securities held by the Fund, except to the extent of his pecuniary interest therein, if any.
F3	On September 28, 2021, outstanding principal and accrued interest underlying a convertible note automatically converted into Common Stock upon the closing of the initial public offering of the Issuer's common stock at a conversion price equal to 80% of the initial public offering price per share.
F4	The shares are held directly by Decheng Capital Global Healthcare Fund (Master), LLC, whose general partner is Decheng Capital Global Healthcare GP, LLC. The reporting person is the sole member and manager of Decheng Capital Global Healthcare GP, LLC. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.